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Speciﬁc strains of Lactobacillus have been found to be beneﬁcial in treating some types of diarrhea and vaginosis. However, a
high mortality rate results from underlying immunosuppressive conditions in patients with Lactobacillus casei bacteremia. Cyclic
AMP(cAMP)is asmall second messenger molecule that mediates signal transduction.Theonset andprogressionofinﬂammatory
responses are sensitive to changes in steady-state cAMP levels. L. casei cell wall extract (LCWE) develops arteritis in mice through
Toll-like receptor-2 signaling. The purpose of this study was to investigate whether intracellular cAMP aﬀects LCWE-induced
pathological signaling. LCWE was shown to induce phosphorylation of the nuclear factor κB( N F - κB) and mitogen-activated
protein kinase (MAPK) signaling pathways and cell proliferation in mice ﬁbroblast cells. Theophylline and phosphodiesterase
inhibitor increased intracellular cAMP and inhibited LCWE-induced cell proliferation as well as phosphorylation of NF-κBa n d
MAPK. Protein kinase A inhibitor H89 prevented cAMP-induced MAPK inhibition, but not cAMP-induced NF-κB inhibition. An
exchange protein activated by cAMP (Epac) agonist inhibited NF-κB activation but not MAPK activation. These results indicate
that an increase in intracellular cAMP prevents LCWE induction of pathological signaling pathways dependent on PKA and Epac
signaling.
1.Introduction
Bacteria stimulate the innate immune system of a host and
the release of inﬂammatory molecules such as cytokines
and chemokines. Lipopolysaccharide (LPS) is an essential
component of the cell wall of gram-negative bacteria, while
peptidoglycan (PGN) is the major component of the cell
wall in gram-positive bacteria. Exposure to LPS or PGN
activates a number of inﬂammatory pathways, including the
transcription factor NF-κB and mitogen-activated protein
kinase (MAPK) pathways [1, 2].
Lactobacillus is a gram-positive, rod-shaped bacterium
ubiquitous in humans and inhabits the mouth and gas-
trointestinal tract. This organism is anaerobic, non-spore-
forming, and nonmotile. Some Lactobacillus strains rep-
resent sources of beneﬁcial organisms termed probiotics,
which are deﬁned as “live microorganisms which when
administered in adequate amounts confer health beneﬁts to2 The Scientiﬁc World Journal
the host” (FAO/WHO, 2001). Lactobacillus can modulate
systemic inﬂammation, cell proliferation, and apoptosis, and
such properties may be useful in immunomodulatory and
cancer prevention strategies [3, 4]. However, approximately
two-thirds of immunocompromised individuals with Lac-
tobacillus casei bacteremia have underlying structural heart
disease or have had a valvular or aortic prosthesis inserted;
these patients are at risk for developing intravascular infec-
tion [5]. Additionally, Lehman et al. [6] reported that single
intraperitoneal injection of a cell wall extract isolated from
L. casei (LCWE) reproducibly leads to the development of
arteritis. Recent studies suggesting signaling via Toll-like
receptors (TLRs) in knockout mice indicate that TLR-2
signaling may play a role in LCWE-induced mouse arteritis
[7]. However, the mechanism of pathogenesis in LCWE-
induced mouse arteritis has not yet been elucidated.
The onset and progression of the inﬂammatory response
are sensitive to changes in steady-state levels of the cyclic
nucleotide cAMP [8]. cAMP is a small, second messen-
ger molecule that mediates signal transduction initiated
by ligand binding to G-protein coupled receptors such
as prostaglandin and adrenergic receptors. Pharmacolog-
ical manipulation of cyclic nucleotide phosphodiesterases
(PDEs), which degrade the cyclic nucleotides cAMP and
cGMP, provides a powerful strategy for regulating biological
processes relayed by these intracellular second messengers
[9].
In this study, we show that theophylline and an
experimental, nonspeciﬁc PDE inhibitor attenuated LCWE-
induced pathological signal transductions and cell prolifer-
ation in a protein kinase A (PKA)—and exchange protein
activated by cAMP (Epac)-dependent manner.
2.MaterialsandMethods
2.1. Chemicals. Theophylline, isobutylmethylxanthine
(IBMX), and Dulbecco’s modiﬁed Eagle’s medium (DMEM)
were obtained from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan). 8-Bromoadenosine-3,5-cyclic monophos-
phate (8-Br-cAMP) and 8-(4-chlorophenylthio)-2-O-
methyladenosine-3,5-cyclic monophosphate sodium salt
(8-CPT-cAMP, Epac activator) were obtained from Biaﬃn
GmbH & Co KG (Kassel, Germany). H89 was obtained
from Calbiochem (La Jolla, CA). Fetal bovine serum (FBS)
was obtained from Invitrogen Corporation (Carlsbad, CA).
Anti-phospho-speciﬁc NF-κB p65 (Ser536), anti-phospho-
speciﬁc p44/42 MAPK (Thr202/Tyr204), anti-β-actin,
horseradish-peroxidase-(HRP-) linked anti-rabbit IgG, and
anti-mouse IgG were purchased from Cell Signaling Tech-
nology, Inc. (Danvers, MA). Anti-phospho-speciﬁc VASP
(Ser157) was obtained from Calbiochem (La Jolla, CA).
2.2. L. casei Cell Wall Fragments. Group B L. casei cell
wall fragments (LCWE) were obtained from L. casei (ATCC
11578) as described [6]. Brieﬂy, the bacteria were disrupted
by overnight incubation in 4% sodium dodecylsulphate
(SDS) in twice their packed volume. Cell wall fragment
preparations were sonicated for 2h. During sonication, cell
wall fragments were maintained at 4◦C. After sonication, cell
wall fragments were centrifuged for 1h at 20,000×ga t4 ◦C,
and the supernatant was retained.
2.3. Cell Culture. NIH 3T3 mouse ﬁbroblast cells were
provided by Dr. Komine (Kanazawa University). The cells
were maintained in DMEM containing 10% FBS at 37◦Ci na
5% CO2 incubator.
2.4. Cell Proliferation Assay. Cell proliferation was analyzed
using the Cell Counting Kit 8 (Wako, Japan). NIH3T3
cells were seeded in 96-well plates at a density of 1 × 103
cells/well. After a 24h incubation, the cells were treated
with LCWE, theophylline, IBMX, 8-Br-cAMP, or 8-CPT-
cAMP for 72h. Next, the cells were incubated with 10μL
WST-8 for 2h. Absorbance of the colored formazan product
produced by mitochondrial dehydrogenases in metabolically
active cells was recorded at 450nm as the background
value. Cell proliferation was expressed as a percentage of
absorbance obtained in treated wells relative to that in
untreated (control) wells.
2.5. NF-κB and p44/42 MAPK (ERK) Activity Assays. To
determine the eﬀect of phosphodiesterase inhibitors or
cAMP analogs on NF-κB and MAPK (ERK) activities, we
investigated phospho-NF-κB and phospho-MAPK (ERK)
levels using various methods. Increases in phospho-NF-κB
and phospho-MAPK (ERK) levels indicate the amount of
NF-κB and MAPK (ERK) signaling activation. NIH3T3 cells
were incubated in DMEM containing serum for 24h and
treated with theophylline (10mM), IBMX (1μM), 8-Br-
cAMP (1mM), or 8-CPT-cAMP (3μM) for 10min with
or without H89 (5μM). Western blotting analyses were
performedusingphospho-NF-κBp65(Ser536)antibodyand
phospho-p44/42 MAPK (Thr202/Tyr204) antibody.
2.6. Western Blotting Analysis. Western blotting was per-
formed as described previously [10]. Brieﬂy, proteins were
extracted from cells, and protein concentrations were deter-
mined using a protein assay. Equal amounts of protein were
separated using 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Resolved proteins were
transferred onto polyvinylidene ﬂuoride (PVDF) mem-
branes, which were incubated with primary antibodies
(1:1000), followed by incubation with HRP-linked sec-
ondary antibodies (1:2000). The blots were developed using
Immobilon Western Chemiluminescence HRP Substrate
(Millipore, Billerica, MA).
2.7. RT-PCR Analysis. To evaluate the expression pattern
of Toll-like receptor-2 (TLR-2) mRNA in the cells, reverse
transcription-mediated polymerase chain reaction (RT-
PCR) was performed as follows. Brieﬂy, RNA was extracted
from the cells and reverse-transcribed by using the reverse
transcriptase ReverTra Ace (TOYOBO, Tokyo, Japan). PCR-
based subtype-speciﬁc gene ampliﬁcation for TLR-2 and β-
actin was performed with LA Taq (Takara, Tokyo, Japan)The Scientiﬁc World Journal 3
pERK
LCWE
PGN
+ − −
−− +
pNF-κB
β-actin
(a)
0
1
2
Cell proliferation
∗
∗
0.5
1.5
R
e
l
a
t
i
v
e
 
p
r
o
l
i
f
e
r
a
t
i
o
n
LCWE
PGN
+ − −
−− +
(b)
Figure 1: Changes in the levels of phospho-NF-κB and phospho-ERK (a) and change in cell proliferation (b) in NIH3T3 mouse ﬁbroblast
cells after treatment with LCWE (10μg/mL) or PGN (10μg/mL). Each column represents the mean ± SEM. ∗P<0.01 versus untreated
controls.
using the sets of primers as follows: 5 -gagtggtgcaagtatgaact-
3  and 5 -ttgcagaagcgctggggaat-3  for TLR-2 and 5 -atg-
gtgggtatgggtcagaag-3  and 5 -ctggggtgttgaaggtctcaa-3  for β-
actin.
2.8. Statistical Analysis. Data are presented as means ± SEM
from at least 3 independent experiments. Statistical analyses
were performed using ANOVA followed by Dunnett’s test,
and results were considered statistically signiﬁcant when P<
0.05.
3. Results
3.1. LCWE and PGN Activate NF-κB, ERK, and Cell Pro-
liferation. Peptidoglycan (PGN) is a major component in
the cell wall of gram-positive bacteria. LCWE was isolated
fromthegram-positivebacteriaL.casei.First,weinvestigated
whether LCWE, as well as PGN, induced the activation
of NF-κB and MAP kinase signaling pathways, that is,
phosphorylation of NF-κB (p65) and ERK1/2, respectively,
in NIH 3T3 ﬁbroblast cells. As shown in Figure 1(a),L C W E
(10μg/mL)aswellasPGN(10μg/mL)signiﬁcantlyincreased
the phosphorylation of NF-κB and ERK, indicating that
LCWE and PGN activate the NF-κB and ERK signaling
pathways in NIH 3T3 ﬁbroblast cells. LCWE and PGN also
accelerated cell proliferation (Figure 1(b)).
3.2. Theophylline Inhibits LCWE-Induced Phosphorylation of
NF-κB and ERK As Well As Cell Proliferation. Theophylline
is a methylxanthine drug used in therapy for asthma, and
a weak and nonselective inhibitor of phosphodiesterases
(PDEs), which break down cyclic nucleotides in the cell,
leading to an increase in intracellular cAMP concentrations
[11, 12]. Vasodilator-stimulated phosphoprotein (VASP) is a
criticalfactorinregulatingactindynamics;increasedlevelsof
phosphorylated VASP are related to increased levels of intra-
cellular cAMP [13, 14]. Expression of phosphorylated VASP
at serine-157 was upregulated after theophylline treatment
(10mM), indicating that theophylline increased intracellular
cAMP concentration under this condition (Figure 2(a)).
LCWE-induced NF-κB and ERK phosphorylation were
signiﬁcantly inhibited by theophylline, suggesting that theo-
phylline prevents LCWE-induced NF-κB and ERK activation
(Figure 2(a)). As shown in Figure 2(b), theophylline com-
pletely prevented LCWE-induced cell proliferation.
3.3. PDE Inhibitor IBMX Inhibits LCWE-Induced Phospho-
rylation of NF-κB and ERK As Well As Cell Prolifera-
tion. Isobutylmethylxanthine (IBMX) is a nonselective PDE
inhibitor that is stronger than theophylline. Pretreating
NIH3T3 mouse ﬁbroblast cells for 30min with IBMX
at a concentration of 1μM led to a marked increase in
VASP phosphorylation (Figure 3(a)), implying that IBMX
signiﬁcantly increases intracellular cAMP concentration.
Figure 3(b) shows that LCWE-induced NF-κBa n dE R K
phosphorylation were signiﬁcantly inhibited by IBMX.
Moreover, IBMX completely abolished LCWE-induced cell
proliferation (Figure 3(b)).
3.4. IBMX Inhibits LCWE-Induced Expression of TLR-2.
Expression of TLR-2, the primary LCWE receptor [7], was
investigatedinNIH3T3mouseﬁbroblastcellsusingRT-PCR.
The intensity of the TLR-2 band increased 16h after LCWE
treatment (Figure 4). However, pretreatment with IBMX
for 30min before LCWE stimulation signiﬁcantly inhibited
LCWE-induced expression of TLR-2 (Figure 4).
3.5. LCWE-Induced Inhibition of NF-κB Phosphorylation
by IBMX Is Independent of PKA, While LCWE-Induced
Inhibition of ERK Activation by IBMX Is Dependent on PKA.
We subsequently examined whether the inhibitory eﬀects of
PDE inhibitor are due to PKA activation. For these studies,
weexaminedtheabilityofthePKAinhibitorH89toabrogate
the ability of IBMX to inhibit LCWE-induced phosphoryla-
tion of NF-κB and ERK. H89, which blocks the catalytic ATP
binding site of PKA, was used at a concentration of 5μM,4 The Scientiﬁc World Journal
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Figure 2: Changes in the levels of phospho-NF-κB, phospho-ERK, and phospho-VASP (a) and change in cell proliferation (b) in NIH3T3
mouse ﬁbroblast cells after treatment with LCWE (10μg/mL) or a combination of theophylline (10mM) and LCWE (10μg/mL). Each
column represents the mean ± SEM. ∗P<0.01 versus untreated controls. #P<0.01 versus LCWE treatment group.
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Figure 3: Changes in the levels of phospho-NF-κB, phospho-ERK, and phospho-VASP (a) and change in cell proliferation (b) in NIH3T3
mouse ﬁbroblast cells after treatment with LCWE (10μg/mL) or a combination of IBMX (1μM) and LCWE (10μg/mL). Each column
represents the mean ± SEM. ∗P<0.01 versus untreated controls. #P<0.01 versus LCWE treatment group.
resulting in the inhibition of PKA-induced phosphorylation
of VASP as shown in Figures 5(a) and 5(d). Pretreating cells
with H89 blocked the ability of IBMX to inhibit LCWE-
induced ERK phosphorylation, but not LCWE-induced NF-
κB phosphorylation (Figure 5). These results indicated that
PDE inhibitor-mediated prevention of ERK is dependent
on PKA activation, but PDE inhibitor-mediated inhibition
of NF-κB phosphorylation may be independent of PKA
activation.
3.6. cAMP Inhibits LCWE-Induced NF-κB Activation via an
Epac-Independent Signaling Pathway. PKA has long been
thought to be the primary eﬀector of cAMP in eukaryotic
cells. However, Epac has recently been discovered to also
function as a target for cAMP [15]. Epac is a guanine
nucleotide exchange protein for the small GTPases Rap
and has been shown to control many cellular processes
previously attributed to PKA. Because we observed no role
for PKA signaling in PDE inhibitor inhibition of NF-κB
phosphorylation in our studies, we shifted our focus to the
potential involvement of Epac.
To further examine the potential signaling role of
Epac, we examined the ability of the Epac-selective agonist
8-(4-chlorophenylthio)-2-O-methyladenosine-3,5-cyclicThe Scientiﬁc World Journal 5
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Figure 4: Change in the expression of TRL-2 (a, b) in NIH3T3 mouse ﬁbroblast cells after treatment with LCWE (10μg / m L )o rac o m -
bination of IBMX (1μM) and LCWE (10μg/mL). Each column represents the mean ± SEM. ∗P<0.01 versus untreated controls. #P<
0.01 versus LCWE treatment group.
monophosphate sodium salt (8-CPT-cAMP) to inhibit
LCWE-induced phosphorylation of NF-κB. 8-CPT-cAMP
is a nonhydrolyzable cAMP analog that activates Epac with
greater potency than PKA [16]. Previous studies have shown
that concentrations of 8-CPT-cAMP as low as 3μMe ﬀec-
tivelyactivateEpacinstudiesusingculturedcells[17].Inour
experiments,weobservedthatpretreatingNIH3T3cellswith
3μM of 8-CPT-cAMP appreciably inhibited LCWE-induced
phosphorylation of NF-κB (Figures 5(e) and 5(f)). However,
3μM of 8-CPT-cAMP failed to signiﬁcantly inhibit LCWE-
induced phosphorylation of ERK (Figures 5(e) and 5(g)).
The cAMP analog 8-bromoadenosine-3,5-cyclic mono-
phosphate (8-Br-cAMP) induced inhibition of NF-κBa n d
ERK phosphorylation by LCWE (Figures 5(e) and 5(g))
similar to the level of IBMX inhibition of LCWE-induced
phosphorylation of NF-κB and ERK. These results strongly
indicate that Epac signaling, but not PKA, is involved in
mediating the inhibition of LCWE-induced phosphorylation
of NF-κB provided by the PDE inhibitor or by direct cAMP
elevation.
3.7. cAMP Inhibits LCWE-Induced Cell Proliferation Depend-
ing on Epac Pathways. Next, we examined the ability of
the PKA inhibitor H89 to abrogate the ability of IBMX
to inhibit LCWE-induced cell proliferation. In Figure 6,
H89 failed to inhibit IBMX-mediated prevention of LCWE-
induced cell proliferation. The Epac activator 8-CPT-cAMP
preventedLCWE-inducedcellproliferation(Figure 6).These
resultsindicatedthatcAMPinhibitionofLCWE-inducedcell
proliferation is dependent on the Epac pathway.
4. Discussion
We showed that intracellular cAMP promotes antiprolif-
erative and anti-inﬂammatory eﬀects in LCWE-stimulated
ﬁbroblast cells via the modulation of NF-κBa n dM A P Ks i g -
naling. Our results show that intracellular cAMP induces the
downregulation of NF-κB and MAPK signaling dependent
on Epac and PKA, respectively.
Speciﬁc strains of Lactobacillus have been found to be
beneﬁcial for treating certain types of diseases [3, 4]. How-
ever, L. casei bacteremia-induced high mortality rates have
been explained based on underlying immunosuppressive
conditions of the patients [5]. Thus, preventive strategies
should be designed to reduce the pathological eﬀects caused
by lactobacilli.
Peptidoglycan is a characteristic cell wall component
of gram-positive bacteria that can stimulate inﬂammatory
signaling in several types of cells. In our study, we found that
peptidoglycan potently induces NF-κB and ERK phosphory-
lation in mouse ﬁbroblast cells (Figure 1(a)). Additionally, it
induces cell proliferation (Figure 1(b)). LCWE is composed
of peptidoglycan and associated uncharged polysaccharides
[18]. It was also found to phosphorylate NF-κBa n dE R Ka t
similar levels to those induced by PGN (Figure 1(a)). LCWE
as well as PGN stimulated cell proliferation (Figure 1(b)).
These results indicate that LCWE may regulate signal
transduction through PGN receptors, speciﬁcally TLR-2
[7]. Interestingly, we observed that LCWE enhances TLR-2
mRNAexpressioninNIH3T3cells(Figure 4).Theregulation
of the receptor by the ligand should be examined in future
studies.
The NF-κB signal pathway plays a crucial role in a
variety of physiological and pathological events, including
inﬂammation, immune responses, and apoptosis. In the
canonical pathway, NF-κB proteins are bound to inhibitory
molecules (IκBs) and are sequestered in the cytoplasm
in an inactive state. When cells are stimulated by the
appropriate factors, the IκB kinase (IKK) complex, contain-
ing catalytically active IKKα and IKKβ and a regulatory
scaﬀold protein IKKγ/NEMO, phosphorylates IκB, leading
to its ubiquitination and proteasomal destruction. NF-κBi s
subsequently phosphorylated and released from inhibition
to enter the nucleus and can either repress or activate gene
transcription, including TLR-2 [19]. Our study showed that
theophylline and IBMX, PDE inhibitors, have an inhibitory
eﬀect on LCWE-induced NF-κB phosphorylation (Figures 2
and 3). These results suggest that PDE inhibitors may inhibit
the TLR-2 receptor expression induced by LCWE (Figure 4).6 The Scientiﬁc World Journal
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Figure 5: Change in the levels of phospho-NF-κB (a, b), phospho-ERK (a, c), and phospho-VASP (a, d) in NIH3T3 mouse ﬁbroblast cells
after treatment with LCWE (10μg/mL), a combination of IBMX (1μM) and LCWE (10μg/mL), or a combination of IBMX (1μM), LCWE
(10μg/mL),andH89(5μM).Changeinthelevelsofphospho-NF-κB(e,f),phospho-ERK(e,g),andphospho-VASP(e,h)inNIH3T3mouse
ﬁbroblast cells after treatment with LCWE (10μg/mL), a combination of 8-Br-cAMP (1mM) and LCWE (10μg/mL), or a combination of 8-
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LCWE treatment group. ##P<0.01 versus LCWE and IBMX treatment group.
Mitogen-activated protein kinases (MAPKs) such as
ERK1/2, JNK1/2, and p38 play key roles in the transduction
of extracellular signals to result in a cellular response.
ERK1/2 can be activated by PGN [20]. In our study, we
found that LCWE potently induces ERK1/2 activation in
mouse ﬁbroblast cells at similar levels to those induced by
PGN (Figures 1(a), 1(b),a n d3(a)). Additionally, our study
described that theophylline and IBMX inhibited LCWE-
induced ERK1/2 activation (Figures 2 and 3).
Elevated levels of cAMP in the cell lead to activation of
diﬀerent cAMP targets, including protein kinase A (PKA)
and the exchange protein directly activated by cAMP (Epac).
The 2 families of cAMP eﬀectors provide a mechanism for
precise and integrated control of cAMP signaling pathwaysThe Scientiﬁc World Journal 7
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#P<0.05 versus LCWE treatment group.
in a spatial and temporal manner. PKA and Epac may act
independently,convergesynergistically,oropposeeachother
inregulatingaspeciﬁccellularfunction[15].Inthisstudy,we
showed that PKA is responsible for cAMP-dependent VASP
phosphorylation and ERK1/2 dephosphorylation, but not
cAMP-dependent NF-κB dephosphorylation (Figure 5). We
also suggest that Epac is responsible for cAMP-dependent
NF-κB dephosphorylation (Figure 5),conﬁrmingthatcAMP
prevents LPS-induced IL-1β production through Epac [21].
Moreover, in this study, we showed that Epac plays a key role
in cAMP-induced inhibition of cell proliferation (Figure 6).
In our recent study, cAMP was shown to inhibit the activity
of Akt through Epac-PTEN pathway activation and in turn
inhibit cell proliferation in glial cells and osteosarcoma cells
[17, 22]. In this study, theophylline and IBMX fully inhibited
cell proliferation (Figures 2(b) and 3(b)) and Akt activation
(data not shown). Theophylline and IBMX may inhibit cell
proliferation through cAMP-induced Epac activation.
Our results provide a new insight into preventing cAMP
action in LCWE-induced-pathological signaling. However,
cAMP-induced inhibition of LCWE signaling in vivo is not
understood. Further studies are necessary to determine the
mechanism underlying cAMP eﬀe c to np r o b i o t i c si nv i v o .
In conclusion, we showed that intracellular cAMP pre-
vents LCWE-induced pathological signal transduction and
cellproliferation.Byunderstandingthesesignaltransduction
pathways, we can design preventive strategies for reducing
the pathological eﬀects caused by lactobacilli.
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